Antiphospholipid Syndrome in Systemic Autoimmune Diseases - 2nd Edition - ISBN: 9780444636553, 9780444636560

Antiphospholipid Syndrome in Systemic Autoimmune Diseases, Volume 12

2nd Edition

Editors: Ricard Cervera Gerard Espinosa Munther Khamashta
eBook ISBN: 9780444636560
Hardcover ISBN: 9780444636553
Imprint: Elsevier Science
Published Date: 29th June 2016
Page Count: 326
Tax/VAT will be calculated at check-out Price includes VAT (GST)
30% off
30% off
30% off
30% off
30% off
20% off
20% off
30% off
30% off
30% off
30% off
30% off
20% off
20% off
30% off
30% off
30% off
30% off
30% off
20% off
20% off
130.00
91.00
91.00
91.00
91.00
91.00
104.00
104.00
185.00
129.50
129.50
129.50
129.50
129.50
148.00
148.00
115.00
80.50
80.50
80.50
80.50
80.50
92.00
92.00
Unavailable
Price includes VAT (GST)
× DRM-Free

Easy - Download and start reading immediately. There’s no activation process to access eBooks; all eBooks are fully searchable, and enabled for copying, pasting, and printing.

Flexible - Read on multiple operating systems and devices. Easily read eBooks on smart phones, computers, or any eBook readers, including Kindle.

Open - Buy once, receive and download all available eBook formats, including PDF, EPUB, and Mobi (for Kindle).

Institutional Access

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

  • List of Contributors
  • Foreword
  • Dedication
  • Chapter 1. History, Classification, and Subsets of the Antiphospholipid Syndrome
    • Abstract
    • 1.1 Introduction
    • 1.2 Historical Perspective
    • 1.3 Classification of APS
    • 1.4 Primary or Isolated APS
    • 1.5 APS Associated With Other Diseases
    • 1.6 Seronegative APS
    • 1.7 Catastrophic APS
    • 1.8 International aPL/APS Congresses
    • 1.9 APS Action
    • References
  • Chapter 2. Epidemiology of the Antiphospholipid Syndrome
    • Abstract
    • 2.1 Introduction
    • 2.2 APS in the General Population
    • 2.3 aPL and Venous Thrombosis
    • 2.4 aPL and Arterial Thrombosis
    • 2.5 aPL and Pregnancy Morbidity
    • 2.6 aPL and SLE
    • 2.7 Conclusions
    • Acknowledgements
    • References
  • Chapter 3. Mechanisms of Action of the Antiphospholipid Antibodies
    • Abstract
    • 3.1 Introduction
    • 3.2 Antiphospholipid Antibodies
    • 3.3 aPL-Mediated Mechanisms of Thrombosis
    • 3.4 aPL-Mediated Mechanism of Pregnancy Complications
    • 3.5 Receptors for β2GPI/Anti-β2GPI Antibodies
    • 3.6 Intracellular Pathways
    • 3.7 Two-Hit Hypothesis
    • 3.8 Genetics and Epigenetics
    • 3.9 Conclusions
    • References
  • Chapter 4. Laboratory Markers With Clinical Significance in the Antiphospholipid Syndrome
    • Abstract
    • 4.1 Introduction
    • 4.2 aPL Detected by Solid-Phase Immunoassays
    • 4.3 Lupus Anticoagulant
    • 4.4 Annexin A5 Resistance Test: A Mechanistic Test for the Detection of Pathogenic aPL Antibodies
    • 4.5 New Technologies for the Detection of aPL
    • 4.6 Which aPL Should Be Tested in Patients With Suspicion of Having APS?
    • 4.7 Conclusions
    • Acknowledgements
    • References
  • Chapter 5. Genetic and Epigenetic Aspects of Antiphospholipid Syndrome: What we knew, what we know
    • Abstract
    • 5.1 HLA, APS, and aPL
    • 5.2 The Role of Non-MHC Genes in APS Susceptibility
    • 5.3 Thrombophilic Hereditary Factors
    • 5.4 Posttranscription Modifications of Anti-β2GPI Antibodies
    • 5.5 Conclusions
    • References
  • Chapter 6. Thrombotic Manifestations of the Antiphospholipid Syndrome
    • Abstract
    • 6.1 Introduction
    • 6.2 Large Vessel Manifestations
    • 6.3 Neurologic Manifestations
    • 6.4 Pulmonary Manifestations
    • 6.5 Cardiac Manifestations
    • 6.6 Renal Manifestations
    • 6.7 Haematologic Manifestations
    • 6.8 Dermatologic Manifestations
    • 6.9 Hepatic and Digestive Manifestations
    • 6.10 Adrenal Manifestations
    • 6.11 Osteoarticular Manifestations
    • 6.12 Catastrophic APS
    • References
  • Chapter 7. Obstetric Manifestations of the Antiphospholipid Syndrome
    • Abstract
    • 7.1 Introduction
    • 7.2 Recurrent Early Pregnancy Loss
    • 7.3 Foetal Death
    • 7.4 Preeclampsia and PI
    • 7.5 Risk Stratification
    • 7.6 Conclusions
    • References
  • Chapter 8. Thrombocytopenia in the Antiphospholipid Syndrome
    • Abstract
    • 8.1 History and Definition
    • 8.2 Prevalence in Primary and Secondary APS
    • 8.3 Pathogenesis
    • 8.4 Treatment
    • 8.5 Immune Thrombocytopenic Purpura
    • 8.6 Heparin-Induced Thrombocytopenia
    • 8.7 Thrombotic Microangiopathy
    • 8.8 Pseudothrombocytopenia
    • 8.9 Disseminated Intravascular Coagulation
    • References
  • Chapter 9. Nonclassification Criteria Manifestations of the Antiphospholipid Syndrome
    • Abstract
    • 9.1 Introduction
    • 9.2 Nonclassification Criteria Manifestations
    • References
  • Chapter 10. Paediatric Antiphospholipid Syndrome
    • Abstract
    • 10.1 Introduction
    • 10.2 Epidemiology
    • 10.3 Clinical Manifestations
    • 10.4 Differential Diagnosis
    • 10.5 Treatment and Outcome
    • References
  • Chapter 11. Antiphospholipid Antibodies and Their Relationship With Infections, Vaccines, and Drugs
    • Abstract
    • 11.1 Introduction
    • 11.2 aPL Associated With Infections
    • 11.3 The Infection Origin of APS
    • 11.4 aPL and Vaccination
    • 11.5 Drug-Induced aPL
    • 11.6 Summary
    • References
  • Chapter 12. Antiphospholipid Syndrome Associated With Malignancies
    • Abstract
    • 12.1 Introduction
    • 12.2 Solid and Haematological Malignancies and aPL
    • 12.3 Catastrophic APS and Malignancies
    • 12.4 Therapeutic Aspects
    • 12.5 Conclusion
    • References
  • Chapter 13. Antiphospholipid Antibodies and Atherosclerosis
    • Abstract
    • 13.1 Introduction
    • 13.2 Clinical Evidence for or Against a Relationship Between aPL and Atherosclerosis
    • 13.3 Classic aPL: Can They Explain All Autoimmune Mechanisms for Atherosclerosis or are They the Tip of an Iceberg?
    • 13.4 Intravascular Autoantibodies: Evidence for Effects on Traditional Cardiovascular Risk Factors
    • 13.5 Natural Autoantibodies: Can They Protect Against Atherosclerosis, and are They Related to aPL?
    • References
  • Chapter 14. Global Antiphospholipid Syndrome Score
    • Abstract
    • 14.1 Introduction
    • 14.2 The Global APS Score
    • 14.3 External Validations of GAPSS
    • 14.4 Conclusion
    • References
  • Chapter 15. Primary Prophylaxis in Patients With Positive Antiphospholipid Antibodies
    • Abstract
    • 15.1 Introduction
    • 15.2 Conclusion
    • References
  • Chapter 16. Treatment of Thrombosis in Antiphospholipid Syndrome
    • Abstract
    • 16.1 Prevention of Recurrent Thrombosis
    • 16.2 Primary Thromboprophylaxis
    • 16.3 New Anticoagulant Drugs
    • 16.4 Other Therapies
    • 16.5 Final Remarks
    • References
  • Chapter 17. Treatment of Catastrophic Antiphospholipid Syndrome
    • Abstract
    • 17.1 Introduction
    • 17.2 Current Approach
    • 17.3 New Approaches
    • 17.4 Conclusions
    • References
  • Chapter 18. Treatment of Pregnancy Complications in Antiphospholipid Syndrome
    • Abstract
    • 18.1 Introduction
    • 18.2 Obstetric Complications Associated with APS
    • 18.3 Mechanisms for Adverse Pregnancy Outcomes
    • 18.4 Therapeutic Options for Women with APS
    • 18.5 Management Algorithm
    • 18.6 Management of Specific Complications
    • 18.7 Conclusions
    • References
  • Chapter 19. Prognosis in Antiphospholipid Syndrome
    • Abstract
    • 19.1 Introduction
    • 19.2 Mortality and Morbidity in Patients with Long-Term Follow-Up APS
    • 19.3 Obstetric APS
    • 19.4 Catastrophic APS
    • References
  • Index

Description

Antiphospholipid Syndrome in Systemic Autoimmune Diseases, Second Edition provides an overview of our current understanding of this major disease. It includes the latest information on the new pathogenetic mechanisms involved, along with clinical manifestations in both the thrombotic and non-thrombotic manifestations of this important disease.

Antiphospholipid syndrome is an autoimmune disease that causes abnormal blood clots. It is now recognized as a major cause of common conditions, including stroke, heart attack, miscarriage, epilepsy, and memory loss, and as such is gaining recognition in all branches of medicine, from obstetrics to cardiology, and from psychiatry to orthopedics.

Key Features

  • Brings the reader up-to-date and allows easy access to individual topics in one place
  • Written by a respected panel of distinguished physicians/scientists actively involved in the field of Antiphospholipid Syndrome
  • Includes box summaries at the end of each chapter that highlight important topics
  • Gives up-to-date, basic knowledge and a modern approach to diagnosis and therapy
  • Provides a comprehensive review of this major disease
  • Includes information on treatment options available

Readership

Researchers, clinicians, clinical investigators, pathologists, medical students, and graduate students in the biomedical sciences, as well as basic scientists in such fields as immunology, rheumatology, genetics, cell biology and molecular biology.


Details

No. of pages:
326
Language:
English
Copyright:
© Elsevier Science 2016
Published:
Imprint:
Elsevier Science
eBook ISBN:
9780444636560
Hardcover ISBN:
9780444636553

About the Editors

Ricard Cervera Editor

Ricard Cervera, MD, PhD, FRCP is Senior Consultant Physician and Head at the Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Head of the Research Team on Systemic Autoimmune Diseases at the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, and Professor at the Department of Medicine, Universitat de Barcelona. Barcelona, Catalonia, Spain, where he coordinates the Masters Course on Autoimmune Diseases. See: http://www.med.ub.es/MIMMUN/PERSONAL/CERVERA/CVCERVER.HTM

Affiliations and Expertise

Department of Autoimmune Diseases, Hospital Clínic,Barcelona, Catalonia, Spain

Gerard Espinosa Editor

Gerard Espinosa, MD, PhD is Consultant at the Department of Autoimmune Diseases, Hospital Clínic, Barcelona, member of the Research Team on Systemic Autoimmune Diseases (coordinator of the Clinical Trials Unit) at the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona and Associate Professor at the Department of Medicine, Universitat de Barcelona, Barcelona, Catalonia, Spain.

Affiliations and Expertise

Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Catalonia, Spain

Munther Khamashta Editor

Munther Khamashta is Professor/Consultant Physician and Director of The Graham Hughes Lupus Research Laboratory at St Thomas’ Hospital, London, and runs a large lupus pregnancy clinic. He studied medicine in Barcelona and internal medicine in Madrid, Spain, where he developed an interest in connective tissue diseases and received his PhD. He was awarded the MRCP in 1999 and FRCP in 2002. He joined the Lupus Unit in London 25 years ago and has been instrumental in developing it into an internationally recognised tertiary centre receiving referrals from all over the UK, see https://kclpure.kcl.ac.uk/portal/en/persons/munther-khamashta(e30b3284-8df1-4cc2-9856-9bca61db843e)/biography.html

Affiliations and Expertise

Graham Hughes Lupus Research Laboratory, The Rayne Institute, St. Thomas’ Hospital, London, England, UK